Protalix BioTherapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 20, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	246	138	130	69	38	118
Market Cap Growth	25.17%	6.60%	87.08%	83.20%	-68.02%	143.47%
Enterprise Value	225	117	115	82	26	141
Last Close Price	3.06	1.88	1.78	1.37	0.83	3.63
PE Ratio	44.30	47.21	15.62	-	-	-
Forward PE	21.10	3.94	-	60.89	-	-
PS Ratio	3.98	2.59	1.98	1.46	0.99	1.88
PB Ratio	4.65	3.20	3.87	-6.52	-6.28	-4.38
P/TBV Ratio	4.65	3.20	3.87	-	-	-
P/FCF Ratio	-	18.73	-	-	-	-
P/OCF Ratio	-	15.96	-	-	-	-
EV/Sales Ratio	3.64	2.19	1.75	1.72	0.68	2.24
EV/EBITDA Ratio	28.91	22.35	9.86	-	-	35.08
EV/EBIT Ratio	35.32	29.80	10.98	-	-	51.93
EV/FCF Ratio	-	15.79	-	-	-	-
Debt / Equity Ratio	0.16	0.13	0.78	-3.15	-5.54	-2.38
Debt / EBITDA Ratio	0.85	0.81	2.00	-	-	11.94
Debt / FCF Ratio	-	0.75	-	-	-	-
Net Debt / Equity Ratio	-0.40	-0.68	-0.55	-1.06	0.91	-0.96
Net Debt / EBITDA Ratio	-2.72	-5.61	-1.57	-0.95	0.28	6.44
Net Debt / FCF Ratio	1.81	-3.96	7.41	-0.44	0.47	-0.97
Asset Turnover	0.86	0.68	0.93	0.74	0.54	1.11
Inventory Turnover	1.37	1.21	1.28	1.13	1.05	1.02
Quick Ratio	2.00	1.49	1.11	0.84	1.29	0.48
Current Ratio	3.03	2.35	1.54	1.38	1.86	0.64
Return on Equity (ROE)	12.64%	7.64%	72.50%	-	-	-
Return on Assets (ROA)	5.53%	3.10%	9.32%	-12.57%	-18.06%	2.99%
Return on Invested Capital (ROIC)	19.78%	18.94%	127.32%	-	-	-
Return on Capital Employed (ROCE)	10.60%	8.20%	26.90%	-55.70%	-50.50%	-14.60%
Earnings Yield	2.19%	2.12%	6.40%	-21.50%	-72.80%	-5.50%
FCF Yield	-4.75%	5.34%	-1.90%	-36.92%	-31.00%	-22.59%
Buyback Yield / Dilution	-15.89%	1.66%	-70.04%	-9.81%	-51.43%	-96.44%

Updated Nov 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q